Combinatorial Analytics & AI Platform

The Combinatorial Analytics & AI Platform by PrecisionLife is a hypothesis-free analytical platform designed to characterize complex chronic diseases by their molecular mechanisms. It is built for drug developers, researchers, and healthcare professionals who need a deeper, more reliable understanding of polygenic disease biology than traditional genomic analysis or AI models can provide. By identifying how multiple genes and other biological factors interact to cause disease, the platform enables precision medicine — personalizing care and improving health outcomes at scale.

Unlike conventional AI models such as LLMs, which are constrained by biased and incomplete training sets, PrecisionLife's combinatorial analytics operates without bias and is infinitely scalable. It produces findings that are both reproducible and explainable, allowing new discoveries to be made faster and with the highest level of confidence. The platform captures non-linear signal within genetic and metabolic networks, revealing combination effects that standard Genome Wide Association Studies (GWAS) and other data models routinely miss.

Core Analytical Capabilities

• Hypothesis-free combinatorial analytics that identifies how multiple genes and factors interact to cause complex diseases
• Analysis of multiomic datasets at massively higher orders of combinations than any other advanced data model
• Detection of non-linear signal in genetic and metabolic networks to uncover deep disease biology
• Generation of richer, more abundant signal from smaller datasets compared to traditional GWAS models
• Unbiased, infinitely scalable architecture producing reproducible and explainable results
• Mechanistic patient stratification to better classify patients according to the origins of their disease

Supported Data Types

• Genomic, metabolomic, proteomic, and transcriptomic data
• Phenotypic, microbiome, and epidemiological data
• Clinical data, imaging, and environmental data
• Pathogen data, structural variants, and digital biomarkers
• Real world evidence and additional multimodal data types, singly or in combination

Demonstrated Performance & Validation

• In a direct comparison with a meta-GWAS of endometriosis patient data published in Nature Genetics by an international consortium, the PrecisionLife platform identified significantly more mechanistic insights from less data with considerably greater replication
• In the COVID-19 case study, the platform outperformed global research efforts, completing analysis 12 months earlier than the COVID-19 Host Genetics Initiative (HGI)
• Identified more loci and more than 7 times the number of novel genes associated with severe COVID-19 compared to any other global research, linking findings to major symptoms of the disease
• COVID-19 findings have since been extensively and independently validated by research groups worldwide, with initial results published in June 2020

Key Platform Outputs

• Patient Stratification Biomarkers: Mechanistic biomarkers that guide drug developers and healthcare professionals toward the most appropriate treatment strategies for individual patients
• DiseaseBank™: A rich repository of mechanistic insights generating chronic disease intellectual property, supporting novel target identification, biomarker discovery, clinical trial design and rescue, and diagnostics

The platform is positioned as an essential tool for the delivery of precision medicine across the drug development lifecycle, de-risking every stage from target identification through to clinical care. Its findings are applicable across a broad range of chronic and complex diseases, and its outputs are designed to integrate with drug development and clinical workflows.